Evidence map›Paper›PMID 36683775›Full record

ArticleJournal of cancer science and clinical therapeutics2022

Systemic Delivery of a Dual PI3K/mTOR Inhibitor More Effective than Topical Delivery in Preventing Anal Carcinogenesis in an HPV Transgenic Mouse Model.

Laura C Gunder, Tyra H Moyer, Marissa R Ziolkowski, Margaret K Keating, Glen E Leverson, Wei Zhang, Evie H Carchman

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer science and clinical therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Laura C GunderDepartment of Surgery, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Tyra H MoyerWaisman Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Marissa R ZiolkowskiDepartment of Surgery, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Margaret K KeatingDepartment of Cell and Regenerative Biology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Glen E LeversonDepartment of Surgery, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Wei ZhangDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Evie H CarchmanDepartment of Surgery, University of Wisconsin-Madison, Madison, Wisconsin, USA.
University of Wisconsin–Madison · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6M
UW Surgical Oncology Research Training Program (UW-SORT)T32CA090217 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Muhammed Murtaza, Heather B Neuman · 2001 to 2026
$8.3M
NCI NIH HHS P30 CA014520NCI NIH HHS T32 CA090217
6 · The paper itself

Abstract

Introduction: Anal dysplasia is a growing health concern that over time can result in squamous cell carcinoma (SqCC) of the anus. In this study, we compare a topical versus systemic (oral) administration of LY3023414, a dual PI3K/mTOR inhibitor, to prevent anal carcinogenesis in a Human Papillomavirus (HPV) mouse model of anal cancer. Materials and Methods: Results: LY3023414 treatment, regardless of the mode of delivery, significantly decreased overt tumor development in mice starting with normal histology and low-grade anal dysplasia. Systemic LY3023414 treatment was more effective in delaying tumor onset than topical treatment. Mice treated with systemic LY3023414 had significantly reduced rates of anal SqCC when starting with normal and low-grade anal dysplasia compared to topical treatment. Topical treatment was only effective in reducing SqCC in the setting of low-grade dysplasia. LY3023414 inhibition of pAKT and pS6 expression varied with starting histology. Neither treatment mode was effective in the setting of high-grade anal dysplasia. Conclusion: Systemic LY3023414 treatment was more effective than topical application in delaying the progression of normal anal histology and low-grade dysplasia to anal cancer in HPV-associated mice.

Indexed as

Anal cancerAnal dysplasiaDual PI3K/mTOR inhibitorLY3023414Squamous cell carcinoma of the anus

Identifiers

PMID36683775
PMCPMC9851170
OpenAlexW4293219305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.